Injectable Therapies for Regional Melanoma

Area of Science:

• Oncology
• Melanoma Research
• Immunotherapy

Background:

• Unresectable melanoma with cutaneous, subcutaneous, or nodal metastases presents a significant clinical challenge.
• Injectable therapies provide a localized treatment option with reduced systemic toxicity for superficial metastases.
• Intralesional treatments can directly eliminate tumor cells or sensitize them to other therapies.

Purpose of the Study:

• To review the role and potential of injectable therapies in managing unresectable melanoma.
• To highlight the current landscape of intralesional melanoma treatments, including approved agents and investigational approaches.

Main Methods:

• Review of existing literature on injectable and intralesional therapies for melanoma.
• Analysis of the clinical application and efficacy of talimogene laherparepvec.
• Discussion of ongoing clinical trials evaluating novel intralesional agents and combination strategies.

Main Results:

• Talimogene laherparepvec is the sole FDA-approved injectable therapy for melanoma in the US.
• Injectable therapies are valued for their ease of intralesional delivery and favorable safety profiles.
• Emerging research focuses on novel intralesional agents and combinations with systemic treatments like checkpoint inhibitors.

Conclusions:

• Injectable therapies represent an important modality for patients with unresectable melanoma metastases.
• The clinical utility of talimogene laherparepvec underscores the potential of intralesional treatment.
• Future directions involve exploring novel agents and synergistic combinations to improve patient outcomes.